ストックスクリーナーアプリを入手
44.39
2.02%
0.88
アフターアワーズ：
44.39
前日終値:
$43.51
開ける：
$43.36
24時間の取引高:
1.23M
Relative Volume:
1.06
時価総額：
$3.57B
収益：
$541.74M
当期純損益:
$88.01M
株価収益率:
40.87
EPS:
1.0862
ネットキャッシュフロー:
$155.34M
1週間 パフォーマンス:
+1.81%
1か月 パフォーマンス:
+10.59%
6か月 パフォーマンス:
+30.41%
1年 パフォーマンス:
+27.63%
1日の値動き範囲:
$42.70
$45.58
1週間の範囲:
$42.20
$46.17
52週間の値動き範囲:
$29.45
$60.91
Veracyte Inc Stock (VCYT) Company Profile
名前
Veracyte Inc
セクター
電話
(650) 243-6300
住所
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, NTRA, A, IQV
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
44.39 | 3.57B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
696.49 | 257.53B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
231.50 | 162.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
404.79 | 58.35B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
175.55 | 49.49B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
271.04 | 44.61B | 16.63B | 1.39B | 2.12B | 8.0674 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-07-15 | 開始されました | Piper Sandler | Overweight |
| 2026-06-02 | 再開されました | Wolfe Research | Outperform |
| 2026-04-13 | 開始されました | Jefferies | Buy |
| 2025-12-02 | 再開されました | Morgan Stanley | Underweight |
| 2025-10-20 | 開始されました | Canaccord Genuity | Hold |
| 2025-03-20 | 開始されました | Craig Hallum | Buy |
| 2024-12-05 | ダウングレード | Goldman | Buy → Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-16 | 開始されました | UBS | Buy |
| 2024-10-10 | 開始されました | Guggenheim | Buy |
| 2024-02-23 | 繰り返されました | Needham | Buy |
| 2023-01-18 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2021-11-18 | 再開されました | Goldman | Buy |
| 2021-06-15 | 開始されました | Raymond James | Outperform |
| 2021-02-18 | 再開されました | Needham | Buy |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2019-07-31 | 開始されました | Lake Street | Buy |
| 2019-07-02 | 開始されました | Needham | Buy |
| 2018-11-29 | ダウングレード | Janney | Buy → Neutral |
| 2018-10-31 | アップグレード | Janney | Neutral → Buy |
| 2017-11-07 | ダウングレード | Janney | Buy → Neutral |
| 2017-11-07 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | 再開されました | BTIG Research | Buy |
| 2016-11-14 | 再開されました | Leerink Partners | Outperform |
| 2015-12-18 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-06-11 | 繰り返されました | Leerink Partners | Outperform |
| 2013-11-26 | 開始されました | William Blair | Outperform |
すべてを表示
Veracyte Inc (VCYT) 最新ニュース
Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms - Zacks Investment Research
Veracyte (NASDAQ:VCYT): Affordable Growth Backed by Strong Fundamentals - ChartMill
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo! Finance Canada
Is Veracyte Inc (VCYT) Overvalued After 3.7% Rally? GF Value Say - GuruFocus
Veracyte Inc. (VCYT) Key Financial Ratios – Valuation, Profitability & More - Value Research
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y - Zacks Investment Research
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now - Zacks Investment Research
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance
Is it the Right Time to Add Phibro Stock to Your Portfolio? - Zacks Investment Research
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets - Zacks Investment Research
Bruker Gains 66.3% in a Year: What's Driving the Rally? - Zacks Investment Research
Reasons to Hold HealthEquity Stock in Your Portfolio for Now - Zacks Investment Research
Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies - Zacks Investment Research
Reasons to Add Globus Medical Stock to Your Portfolio Now - Zacks Investment Research
Charles River Gains 75.8% in a Year: What's Driving the Rally? - Zacks Investment Research
Is This the Right Time to Add TMO Stock to Your Portfolio? - Zacks Investment Research
Cathie Wood’s ARK sells Teradyne stock, buys Veracyte - Investing.com
Veracyte Inc (VCYT) Shares Fall 6.3% -- What GF Score of 79 Tells Investors - GuruFocus
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up - TradingView
Veracyte stock falls 4.64 percent as Decipher data draw focus - AD HOC NEWS
Is It Prudent to Add Teleflex Stock to Your Portfolio Now? - Zacks Investment Research
A Look at Veracyte Inc (VCYT) After 4.1% Gain -- GF Value $39.27 vs Price $47.67 - GuruFocus
Veracyte, Inc. (VCYT) Stock forecasts - Yahoo Finance UK
Veracyte (VCYT) Is Down 9.0% After New Level 1B1 Decipher Prostate Data at ASTRO 2026 - Yahoo Finance
Veracyte Inc (VCYT) Stock Down 4.0% but Still Overvalued -- GF Score: 81/100 - GuruFocus
Neogen Stock Rallies 83% YTD: What's Driving the Surge? - Zacks Investment Research
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care - Zacks Investment Research
10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises - Zacks Investment Research
Should You Continue to Hold IART Stock in Your Portfolio? - Zacks Investment Research
ETFs Investing in Veracyte, Inc. Stocks - tradingview.com
Preferred dividends of Veracyte, Inc. – HAN:12V - TradingView
Return on equity % of Veracyte, Inc. – HAN:12V - TradingView
Veracyte, Inc. Cash Flow – HAN:12V - TradingView
Veracyte Inc. (VCYT) Holds Midpoint of Trading Range After 1.88% AdvanceFactor Rotation - siam.in
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now - Zacks Investment Research
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - Zacks Investment Research
For 44% with low scores, added hormone therapy showed no statistically significant benefit against 10-year cancer spread. - Stock Titan
Is This the Right Time to Add Labcorp Stock to Your Portfolio? - Zacks Investment Research
Weekly Recap: Decipher studies at ASTRO 2026 and ARKG buys Veracyte, Inc. - TradingView
Veracyte Inc. R (12V.MU) Q1 FY2026 earnings call transcript - Yahoo Finance
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 - The Manila Times
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 - GlobeNewswire Inc.
Eight studies will examine who with prostate cancer may benefit from more treatment - Stock Titan
Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains? - Yahoo Finance
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today - Eastern Progress
Is Veracyte Inc (VCYT) Overvalued After 10.8% Rally? GF Value Sa - GuruFocus
A Veracyte (VCYT) director plans a $352,500 share sale after selling 5,000 shares. - Stock Titan
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo! Finance Canada
Veracyte Inc (VCYT) 財務データ
収益
当期純利益
現金流量
EPS
Veracyte Inc (VCYT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| JOHN LEITE | Officer |
Sep 21 '26 |
Proposed Sale |
39.80 |
4,015 |
159,777 |
0 |
| Leite John | Global Chief Commercial Off |
Sep 21 '26 |
Sale |
40.00 |
4,015 |
160,600 |
124,329 |
| JENS HOLSTEIN | Director |
Sep 14 '26 |
Proposed Sale |
40.95 |
5,000 |
204,747 |
0 |
| Holstein Jens | Director |
Sep 14 '26 |
Sale |
40.95 |
5,000 |
204,747 |
27,471 |
| ANN MCGUIRE | Officer |
Sep 04 '26 |
Proposed Sale |
44.67 |
3,254 |
145,356 |
0 |
| McGuire Annie | EVP, General Counsel |
Sep 04 '26 |
Sale |
43.09 |
3,254 |
140,212 |
131,160 |
| Chambers Rebecca | Chief Financial Officer |
Sep 04 '26 |
Sale |
43.10 |
3,652 |
157,394 |
166,025 |
| Febbo Phillip G. | Chief Scientific & Med Officer |
Sep 04 '26 |
Sale |
43.05 |
13,110 |
564,410 |
133,048 |
| PHILLIP FEBBO | Officer |
Sep 04 '26 |
Proposed Sale |
44.67 |
13,110 |
585,624 |
0 |
| REBECCA CHAMBERS | Officer |
Sep 04 '26 |
Proposed Sale |
44.67 |
3,652 |
163,135 |
0 |
3.07%
0.16%
大文字化:
|
ボリューム (24 時間):